The comparison the effect of flaxseed and Conjugated Estrogen vaginal cream in vaginal atrophy and sexual satisfaction of postmenopausal women.

Phase 3

Recruiting

Conditions: atrophy and sexual satisfaction.
Postmenopausal atrophic vaginitis

Registration Number: IRCT20181027041473N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 70

Inclusion Criteria

Having a willingness to participated in the study
Married and have sexual activity
age range of 40-65 years
Have literacy to read and write
Amenorrhoea has been followed for at least 12 months or 6 months amenorrhoea with FSH> 40.
Have normal Pap smear in the past 3 years
Clinic diagnosis of vaginal atrophy through a set of criteria including: score 65 or more (based on the VAS visual criteria) of the scale of the most vaginal annoyance symptoms (MBS) and having at least 2 signs of the descriptive evaluation table of vaginal mucus, PH> 5 and VMV=55 (vaginal maturation grade).

Exclusion Criteria

Abnormal bleeding vaginal (pink to brown spotting or clear bleeding).
have chronic illness such as diabetes, arthritis, cardiovascular disease, active liver disease or gallbladder disease.
having vaginal infection
allergy to estrogen or flax seed compounds
don't suffering of endometrial cancer or breast cancer
Endometrial cancer or breast cancer known or suspected .
Consumer Products hormonal vaginal or transdermal than 4 weeks prior to the study and use of oral estrogen, uterine progesterone 8 weeks before the study and use of implants progesterone and estrogen injections for 3 months and pellets of estrogen and progesterone injections 6 months prior to the study to be

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Atrophy and sexual satisfaction treatment. Timepoint: Performing the intervention then measuring vaginal atrophy and sexual satisfaction in the fourth and eighth weeks. Method of measurement: Using vaginal maturation index of more than 55 and a vaginal pH of more than 5 and gaining a score of 65 or more from the scale of the most vaginal annoying symptoms and having at least two signs of the symptoms of a descriptive evaluation table of vaginal mucus.

Secondary Outcome Measures